Critical Reviews in Oncology/Hematology (open access),

Clinical Considerations for the Use of FLT3 Inhibitors in Acute Myeloid Leukemia

Publication date: Available online 28 June 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Taylor M. Weis, Bernard L. Marini, Dale L. Bixby, Anthony J. PerissinottiAbstractInternal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3 (FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis. Midostaurin, a multikinase inhibitor that targets FLT3, demonstrated a survival benefit in FLT3-mutated AML in combination with front-line...

Critical Reviews in Oncology/Hematology (open access)

Sat Jun 29, 2019 15:07

Germinal immunogenetics as a predictive factor for immunotherapy

Publication date: Available online 28 June 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Sadal Refae, Jocelyn Gal, Patrick Brest, Gerard MilanoAbstractClinical response to checkpoint inhibitors-based (CPIs) therapies can vary among tumor types and between patients. This led to a significant amount of pre-clinical and clinical research into biomarker identification. Biomarkers have been found to cover both the tumor itself and the tumor microenvironment. Entering host-related parameters...

Critical Reviews in Oncology/Hematology (open access)

Sat Jun 29, 2019 15:07

Primary central nervous system lymphoma: novel precision therapies

Publication date: Available online 27 June 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Patrizia Mondello, Michael Mian, Francesco BertoniAbstractPrimary central nervous system lymphoma (PCNSL) is a rare and aggressive form of diffuse large B-cell lymphoma. The frontline treatment with high-dose methotrexate based immunochemotherapy is not curative for the majority of patients. Gene expression profiling and next-generation sequencing have recently provided plethora of data shedding...

Critical Reviews in Oncology/Hematology (open access)

Fri Jun 28, 2019 18:52